{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04104451",
      "OrgStudyIdInfo": {
        "OrgStudyId": "19-1113"
      },
      "Organization": {
        "OrgFullName": "University of Colorado, Denver",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "PHASE 1, OPEN-LABEL SAFETY STUDY OF UMBILICAL CORD LINING MESENCHYMAL STEM CELLS (CORLICYTE®) TO HEAL CHRONIC DIABETIC FOOT ULCERS",
      "OfficialTitle": "PHASE 1, OPEN-LABEL SAFETY STUDY OF UMBILICAL CORD LINING MESENCHYMAL STEM CELLS (CORLICYTE®) TO HEAL CHRONIC DIABETIC FOOT ULCERS"
    },
    "StatusModule": {
      "StatusVerifiedDate": "October 2021",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "November 12, 2019",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "September 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "September 20, 2019",
      "StudyFirstSubmitQCDate": "September 23, 2019",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "September 26, 2019",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "October 26, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 27, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "University of Colorado, Denver",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Study Objective:\n\nThe objective of this Phase 1 open-label study is to establish the safety and tolerability of Corlicyte mesenchymal stem cells (MSCs) in the treatment of patients with chronic diabetic foot ulcers (DFUs)."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Diabetic Foot Ulcer"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Sequential Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "20",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Dose 1",
            "ArmGroupType": "Experimental",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Corlicyte"
              ]
            }
          },
          {
            "ArmGroupLabel": "Dose 2",
            "ArmGroupType": "Experimental",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Corlicyte"
              ]
            }
          },
          {
            "ArmGroupLabel": "Dose 3",
            "ArmGroupType": "Experimental",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Corlicyte"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Corlicyte",
            "InterventionDescription": "expanded umbilical cord lining mesenchymal stem cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Dose 1",
                "Dose 2",
                "Dose 3"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "SAE",
            "PrimaryOutcomeDescription": "Number and percent of subjects in each dosing cohort and overall with a serious adverse reaction to Corlicyte®.",
            "PrimaryOutcomeTimeFrame": "throughout study completion, an average of 4 months per subject"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Antibodies to HLA Class I - number and percent",
            "SecondaryOutcomeDescription": "1. Number and percent of subjects who develop a high titer of antibodies to human leukocyte antigen (HLA) Class I molecules expressed on Corlicyte®",
            "SecondaryOutcomeTimeFrame": "throughout study completion, an average of 4 months per subject"
          },
          {
            "SecondaryOutcomeMeasure": "Antibodies to HLA Class I - Time To Development",
            "SecondaryOutcomeDescription": "2. Time to development of high titer of antibodies to HLA Class I molecules expressed on Corlicyte®",
            "SecondaryOutcomeTimeFrame": "throughout study completion, an average of 4 months per subject"
          },
          {
            "SecondaryOutcomeMeasure": "Increase Ulcer Size",
            "SecondaryOutcomeDescription": "3. Number and percent of subjects with an increase in ulcer size by the end of the Treatment Phase as reviewed by the Wound Core Laboratory (WCL).",
            "SecondaryOutcomeTimeFrame": "throughout study completion, an average of 4 months per subject"
          },
          {
            "SecondaryOutcomeMeasure": "Adverse Reaction",
            "SecondaryOutcomeDescription": "4. Number and percent of subjects with an adverse reaction to Corlicyte® in each cohort and overall.",
            "SecondaryOutcomeTimeFrame": "throughout study completion, an average of 4 months per subject"
          },
          {
            "SecondaryOutcomeMeasure": "Suspected Adverse Reaction",
            "SecondaryOutcomeDescription": "5. Number and percent of subjects with a suspected adverse reaction to Corlicyte® in each cohort and overall.",
            "SecondaryOutcomeTimeFrame": "throughout study completion, an average of 4 months per subject"
          },
          {
            "SecondaryOutcomeMeasure": "Suspected Serious Adverse Reaction",
            "SecondaryOutcomeDescription": "6. Number and percent of subjects with a suspected serious adverse reaction to Corlicyte® in each cohort and overall.",
            "SecondaryOutcomeTimeFrame": "throughout study completion, an average of 4 months per subject"
          },
          {
            "SecondaryOutcomeMeasure": "Change in A1c",
            "SecondaryOutcomeDescription": "7. Change in hemoglobin A1c from Screening to End-of-Study/Early Termination",
            "SecondaryOutcomeTimeFrame": "throughout study completion, an average of 4 months per subject"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nInclusion Criteria:\n\nMales or non-pregnant, non-lactating females.\nAge 18 or greater at the time of informed consent.\nAble and willing to provide written informed consent.\nType 1 or Type 2 diabetes.\n\nChronic DFU as the index ulcer meeting all of the following criteria:\n\npresent for at least 4 weeks at the time of Screening Visit 1\nlocated below the malleoli of the foot\nextends to the dermis or subcutaneous tissue, surrounded by healthy skin, without evidence of exposed muscle, tendon, bone, or joint capsule\narea measures 1 to 10 cm2 inclusive, at Screening Visit 1, and\nnon-healing (defined as ≤50% reduction in ulcer size by the Baseline Visit, as compared to Screening Visit 1).\nNegative for antibodies to HLA Class I molecules expressed on Corlicyte MSCs, as measured by Luminex HLA single antigen beads, within 3 months prior to start of Treatment Phase without interval sensitizing events.\nFor an index ulcer on the plantar surface of the foot, willingness to offload the foot per study protocol.\nIn women of childbearing potential, willingness to use effective means of birth control during the course of the study; if using systemic birth control, this must have been used for 6 months or longer prior to Screening Visit 1.\n\nExclusion Criteria:\n\nExclusion Criteria:\n\nPlanned DFU treatment to the index ulcer that includes enzymatic agents, cytotoxic agents or any substance(s) that would affect MSC survival during the study period.\nWomen planning to become pregnant during the course of the study.\nSignificant history of, or current evidence of a severe comorbid medical or psychiatric condition such as liver disease, end-stage renal disease, untreated proliferative retinopathy, bleeding diathesis, schizophrenia, or laboratory abnormality that, in the opinion of the Investigator, would preclude enrollment because of unacceptable risk.\nPresence of any skin condition or skin disorder around the index ulcer that might interfere with the diagnosis of or assessment of study-related endpoints, such as atopic dermatitis, eczema, psoriasis, or seborrheic dermatitis.\nPresence of actinic keratosis or skin cancer within 2 cm of the index ulcer.\nCellulitis or other active infection of the index ulcer or any non-index ulcer at Screening.\nUse of an investigational agent for ulcer care within 30 days prior to Screening Visit 1.\nReceipt of an investigational agent or device not approved by the US FDA for marketed use in any indication within 30 days prior to Screening Visit 1.\nPlanned participation in another therapeutic study for any indication prior to completion of study participation.\nUnwillingness or inability to comply with study visits and study procedures for the entire duration of study participation.\nKnown positivity for Human Immunodeficiency Virus (HIV).\nActive osteomyelitis or gangrene of either foot at Screening.\nKnown Methicillin-resistant Staphylococcus aureus (MRSA) infection within 30 days prior to Screening Visit 1.\nPoorly-controlled diabetes mellitus, defined as hemoglobin A1c (HbA1c) >12%.\nUnsuitable for cellular therapy for any reason, in the opinion of the Investigator.\nPlanned use of cell therapy or amniotic membrane treatment for the index ulcer during study participation.\nSignificant titer of antibodies to HLA Class I molecules expressed on Corlicyte MSCs, as measured by Luminex HLA single antigen beads.\nPresence of severe peripheral artery disease (PAD) defined as clinical evidence of critical limb ischemia (CLI) during Screening.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Cecilia Low Wang, MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "303-724-7801",
            "CentralContactEMail": "Cecilia.LowWang@CUAnschutz.edu"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Cecilia Low Wang, MD",
            "OverallOfficialAffiliation": "University of Colorado, Denver",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "University of Colorado Anschutz Medical Campus",
            "LocationStatus": "Recruiting",
            "LocationCity": "Aurora",
            "LocationState": "Colorado",
            "LocationZip": "80045",
            "LocationCountry": "United States",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Nicola Haakonsen",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "720-848-2425"
                }
              ]
            }
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000017719",
            "ConditionMeshTerm": "Diabetic Foot"
          },
          {
            "ConditionMeshId": "D000016523",
            "ConditionMeshTerm": "Foot Ulcer"
          },
          {
            "ConditionMeshId": "D000014456",
            "ConditionMeshTerm": "Ulcer"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000003925",
            "ConditionAncestorTerm": "Diabetic Angiopathies"
          },
          {
            "ConditionAncestorId": "D000014652",
            "ConditionAncestorTerm": "Vascular Diseases"
          },
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          },
          {
            "ConditionAncestorId": "D000007871",
            "ConditionAncestorTerm": "Leg Ulcer"
          },
          {
            "ConditionAncestorId": "D000012883",
            "ConditionAncestorTerm": "Skin Ulcer"
          },
          {
            "ConditionAncestorId": "D000012871",
            "ConditionAncestorTerm": "Skin Diseases"
          },
          {
            "ConditionAncestorId": "D000048909",
            "ConditionAncestorTerm": "Diabetes Complications"
          },
          {
            "ConditionAncestorId": "D000003920",
            "ConditionAncestorTerm": "Diabetes Mellitus"
          },
          {
            "ConditionAncestorId": "D000004700",
            "ConditionAncestorTerm": "Endocrine System Diseases"
          },
          {
            "ConditionAncestorId": "D000003929",
            "ConditionAncestorTerm": "Diabetic Neuropathies"
          },
          {
            "ConditionAncestorId": "D000005534",
            "ConditionAncestorTerm": "Foot Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M16358",
            "ConditionBrowseLeafName": "Ulcer",
            "ConditionBrowseLeafAsFound": "Ulcer",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M19085",
            "ConditionBrowseLeafName": "Diabetic Foot",
            "ConditionBrowseLeafAsFound": "Diabetic Foot",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M18071",
            "ConditionBrowseLeafName": "Foot Ulcer",
            "ConditionBrowseLeafAsFound": "Foot Ulcers",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M6272",
            "ConditionBrowseLeafName": "Diabetic Angiopathies",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16552",
            "ConditionBrowseLeafName": "Vascular Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10035",
            "ConditionBrowseLeafName": "Leg Ulcer",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14838",
            "ConditionBrowseLeafName": "Skin Ulcer",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14826",
            "ConditionBrowseLeafName": "Skin Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6267",
            "ConditionBrowseLeafName": "Diabetes Mellitus",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M25157",
            "ConditionBrowseLeafName": "Diabetes Complications",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7014",
            "ConditionBrowseLeafName": "Endocrine System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6276",
            "ConditionBrowseLeafName": "Diabetic Neuropathies",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7810",
            "ConditionBrowseLeafName": "Foot Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC19",
            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC18",
            "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC05",
            "ConditionBrowseBranchName": "Musculoskeletal Diseases"
          }
        ]
      }
    }
  }
}